Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $14.09 in the last session, up 1.22% from day before closing price of $13.92. In other words, the price has increased by $1.22 from its previous closing price. On the day, 0.77 million shares were traded. DAWN stock price reached its highest trading level at $14.19 during the session, while it also had its lowest trading level at $13.55.
Ratios:
We take a closer look at DAWN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.09 and its Current Ratio is at 4.09. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 01, 2024, Upgraded its rating to Buy and sets its target price to $24 from $11 previously.
On April 24, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $30 to $33.
BofA Securities Downgraded its Buy to Underperform on April 25, 2023, whereas the target price for the stock was revised from $34 to $9.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 16 ’24 when Dubow Adam sold 3,202 shares for $14.00 per share. The transaction valued at 44,825 led to the insider holds 26,928 shares of the business.
York Charles N II sold 2,633 shares of DAWN for $36,860 on Aug 16 ’24. The COO, CFO AND SECRETARY now owns 232,485 shares after completing the transaction at $14.00 per share. On Aug 16 ’24, another insider, Blackman Samuel C., who serves as the HEAD OF R&D of the company, sold 2,232 shares for $14.00 each. As a result, the insider received 31,246 and left with 1,127,535 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1385218944 and an Enterprise Value of 874868800. For the stock, the TTM Price-to-Sale (P/S) ratio is 150.98 while its Price-to-Book (P/B) ratio in mrq is 4.03. Its current Enterprise Value per Revenue stands at 106.796 whereas that against EBITDA is -3.047.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $9.67. The 50-Day Moving Average of the stock is 0.54%, while the 200-Day Moving Average is calculated to be -1.47%.
Shares Statistics:
According to the various share statistics, DAWN traded on average about 1.00M shares per day over the past 3-months and 777400 shares per day over the past 10 days. A total of 87.23M shares are outstanding, with a floating share count of 59.16M. Insiders hold about 32.59% of the company’s shares, while institutions hold 73.49% stake in the company. Shares short for DAWN as of 1722384000 were 12207385 with a Short Ratio of 12.20, compared to 1719532800 on 10442384. Therefore, it implies a Short% of Shares Outstanding of 12207385 and a Short% of Float of 17.34.
